✨ Free AI Report
Almirall, S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Almirall, S.A.
Company Research

Almirall, S.A.: Business Overview, Financials & Competitive Analysis

Almirall is a Spanish pharmaceutical company dedicated to medical dermatology, headquartered in Barcelona and founded in 1944. In 2023, the company generated total revenues of €898.8 million and was the leading Europe...

Analyst-debate audio for Almirall, S.A.

AskCyborg analysts argue the bull and bear cases for Almirall, S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Almirall is a focused dermatology specialist with market leadership in Europe, strong commercial infrastructure, and emerging...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Medical Dermatology
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Almirall, S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Almirall, S.A. Overview

Pro stress-test →

Almirall is a Spanish pharmaceutical company dedicated to medical dermatology, headquartered in Barcelona and founded in 1944. In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology. The company operates globally with a specialized focus on dermatological treatments across multiple therapeutic areas.

Strategic Profile

Pro stress-test →

In 2014 Almirall divested its respiratory franchise to Astrazeneca, focusing on dermatology, and has pursued strategic acquisitions to expand its dermatology portfolio. Almirall operates a global network with over 1,800 employees, 15 subsidiaries, and distribution in over 100 countries across 5 continents. The company is leveraging AI-driven innovation in drug discovery to strengthen its competitive position in the dermatology space.

Competitive Landscape

Pro stress-test →

Key competitors include AbbVie Inc., Pfizer Inc., GSK plc, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd., Galderma, and Amgen Inc. Almirall's competitive advantage lies in its focused geographic leadership in Europe, specialized dermatology expertise, and expanding biologics portfolio within a niche but growing therapeutic segment.

Industry Context

Almirall, S.A. operates in Biopharmaceuticals - Medical Dermatology.

Key facts

Founded: 1944 · Headquarters: Barcelona, Spain · Employees: 2,000+ · Revenue: €990M (2024)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Almirall, S.A..

  • The company is the leading European company in medical dermatology with an expanding biologics portfolio and a robust pipeline of novel therapeutics.
  • Almirall and Absci announced expansion of their AI Drug Discovery collaboration with a second dermatology target, combining Absci's Integrated Drug Creation platform with Almirall's dermatology expertise.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2025Expanded AI drug discovery collaboration with Absci, selecting second dermatology target
  • May 2025Q1 2025 results showed strong sales growth in line with longer-term trajectory
  • +1 moreTrack every material event for Almirall, S.A. as it happens. Explore monitoring →
Get alerted when Almirall, S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

DupilumabLeading biologic for atopic dermatitis→SkyriziRisankizumab for psoriasis→OpsumitPulmonary hypertension and dermatology treatments→Dermatological PortfolioEuropean dermatology specialist→

Compare Almirall, S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Almirall, S.A. operates in Biopharmaceuticals - Medical Dermatology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Medical Dermatology research →
NEW · MCP server

Ask your AI assistant about Almirall, S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Almirall, S.A. and its top competitor on Cyborg Score”
“What did Almirall, S.A. do this quarter?”
“Is Almirall, S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Almirall, S.A. do?+
Almirall is a Spanish pharmaceutical company dedicated to medical dermatology, headquartered in Barcelona and founded in 1944. In 2023, the company generated total revenues of €898.8 million and was the leading Europe...
What is Almirall, S.A.'s Cyborg Score?+
Almirall, S.A. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Almirall, S.A.'s main competitors?+
Named competitors include Dupilumab, Skyrizi, Opsumit, Dermatological Portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full Almirall, S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Almirall, S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Almirall, S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.